A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients
2001
AbstractPurpose: To evaluate the 24-week impact of saquinavir-enhancing antiretroviral therapy on viral replication in patients previously treated with nucleoside analogues with or without prior saquinavir hard-gel capsules (HGC). Method: Patients were randomized in three groups to receive the following: Group 1—nelfinavir (750 mg tid), saquinavir soft-gel capsule (SGC) (800 mg tid), and stavudine (40 mg bid); Group II—ritonavir (400 mg bid), saquinavir-SGC (400 mg bid), and stavudine (40 mg bid); or Group III—delavirdine (400 mg tid), saquinavir-SGC (800 mg tid), and stavudine (40 mg bid). Viral loads, CD4 count, and safety were assessed over a 24-week period with an additional 6-month follow-up. Results: 73 patients received randomized therapy; 14 of whom were SQV naive, with a median baseline viral load of 3.6 log10 and a CD4 count of 370 cells/mm3. By 6 months, the median decreases in plasma viral loads were 0.26, 0.71, and 0.29 log10 copies/mL for groups I, II, and III, respectively. The median incre...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
32
References
6
Citations
NaN
KQI